NF-kB and Fibrosis

NF-κB and Fibrosis: A Detailed Overview

Nuclear Factor-kappa B (NF-κB) is a transcription factor that plays a pivotal role in inflammation, immunity, cell survival, and apoptosis. Dysregulation of NF-κB signaling is a key driver of chronic inflammatory diseases, cancer, and fibrosis. Fibrosis is a pathological process marked by excessive extracellular matrix (ECM) deposition, tissue scarring, and organ dysfunction, and NF-κB is central to its initiation and progression.

---

Mechanisms of NF-κB in Fibrosis

1. NF-κB Activation in Fibrosis

NF-κB becomes activated in response to various stimuli, such as:

• Pro-inflammatory cytokines: Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β).
• Pathogen-associated molecular patterns (PAMPs): Lipopolysaccharides (LPS) from microbes.
• Damage-associated molecular patterns (DAMPs): Reactive oxygen species (ROS), cellular debris.
• Mechanical stress: Tissue injury or organ damage.

NF-κB activation occurs through two major pathways:

• Canonical Pathway: Involves the degradation of the inhibitor of κB (IκB), allowing NF-κB dimers (e.g., p65/p50) to translocate into the nucleus and regulate gene transcription.
• Non-Canonical Pathway: Involves processing of p100 into p52, forming RelB/p52 complexes that regulate a distinct set of genes.

---

2. Inflammation as a Driver of Fibrosis

• NF-κB is a master regulator of inflammation and induces the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and chemokines (e.g., MCP-1).
• Chronic inflammation leads to the recruitment and activation of immune cells, such as macrophages, neutrophils, and lymphocytes.
• These immune cells release additional cytokines, perpetuating the inflammatory cycle and driving the activation of fibrogenic cells like fibroblasts and myofibroblasts.

---

3. Activation of Fibrogenic Cells

• Fibroblasts and Myofibroblasts: NF-κB promotes the activation of these cells, which are the primary producers of ECM components like collagen and fibronectin.
• Hepatic Stellate Cells (HSCs): In liver fibrosis, NF-κB drives the activation of HSCs, leading to excessive ECM deposition.
• TGF-β Upregulation: NF-κB increases the expression of transforming growth factor-beta (TGF-β), a master regulator of fibrosis. TGF-β further activates fibroblasts and myofibroblasts, amplifying ECM production.

---

4. Crosstalk with Other Fibrotic Pathways

NF-κB interacts with other signaling pathways to amplify fibrotic processes:

• TGF-β/Smad Pathway: NF-κB enhances TGF-β signaling, which is central to fibrosis.
• Wnt/β-Catenin Pathway: NF-κB interacts with Wnt signaling to promote fibroblast activation.
• Oxidative Stress: NF-κB promotes the production of ROS, which further activates fibrogenic pathways.

---

5. Inhibition of ECM Degradation

• NF-κB upregulates tissue inhibitors of metalloproteinases (TIMPs), which inhibit matrix metalloproteinases (MMPs). This reduces ECM degradation and promotes ECM accumulation, leading to tissue scarring.

---

NF-κB in Specific Fibrotic Diseases

1. Liver Fibrosis

• Chronic liver diseases such as hepatitis B/C, alcoholic liver disease, and non-alcoholic steatohepatitis (NASH) activate NF-κB in Kupffer cells, hepatocytes, and hepatic stellate cells.
• NF-κB drives the production of TGF-β and pro-inflammatory cytokines, leading to collagen deposition and fibrosis progression.

2. Pulmonary Fibrosis

• In idiopathic pulmonary fibrosis (IPF), NF-κB is activated in alveolar macrophages, epithelial cells, and fibroblasts.
• This promotes inflammation, fibroblast activation, and ECM production, contributing to lung scarring.

3. Renal Fibrosis

• In chronic kidney disease (CKD), NF-κB activation in tubular epithelial cells and interstitial fibroblasts drives inflammation, fibroblast activation, and ECM deposition.

4. Cardiac Fibrosis

• NF-κB contributes to myocardial fibrosis in response to ischemia, hypertension, or pressure overload.
• It promotes fibroblast activation, TGF-β signaling, and collagen deposition in the heart.

---

Key Molecular Players in NF-κB-Mediated Fibrosis

| Molecule | Role in Fibrosis |

|------------------------|-------------------------------------------------------------------------------------|

| TGF-β | Master regulator of fibrosis; upregulated by NF-κB. |

| IL-1β, TNF-α | Pro-inflammatory cytokines driving fibrogenesis. |

| PDGF | Stimulates fibroblast proliferation and ECM production. |

| MCP-1 (CCL2) | Recruits monocytes/macrophages, amplifying inflammation and fibrosis. |

| TIMP-1, TIMP-2 | Inhibit ECM degradation, promoting ECM accumulation. |

| ROS | Enhances NF-κB activation and drives oxidative stress-related fibrogenesis. |

---

Therapeutic Implications: Targeting NF-κB in Fibrosis

Given its central role in fibrosis, NF-κB is an attractive therapeutic target. Strategies to modulate NF-κB activity include:

1. NF-κB Inhibitors

• IKK Inhibitors: Block IκB kinase activity, preventing IκB degradation and NF-κB activation.
• Example: BAY 11-7082 (experimental inhibitor).
• Proteasome Inhibitors: Prevent degradation of IκB, retaining NF-κB in its inactive state.
• Example: Bortezomib (FDA-approved for multiple myeloma, under investigation for fibrosis).

2. Anti-Inflammatory Therapies

• TNF-α Inhibitors: Blockade of upstream cytokines like TNF-α (e.g., infliximab) can reduce NF-κB activation.
• IL-1β Inhibitors: Drugs like anakinra target IL-1β, reducing inflammation.

3. Antioxidants

• Agents like N-acetylcysteine (NAC) reduce oxidative stress, indirectly suppressing NF-κB activation.

4. TGF-β Inhibition

• Targeting TGF-β signaling downstream of NF-κB can attenuate fibrosis.
• Example: Fresolimumab (anti-TGF-β monoclonal antibody).

5. Modulation of Gut-Liver Axis

• In liver fibrosis, strategies to reduce gut-derived PAMPs (e.g., probiotics, antibiotics) can decrease NF-κB activation in Kupffer cells.

---

Conclusion

NF-κB is a central mediator of fibrosis, driving inflammation, fibroblast activation, TGF-β production, and ECM deposition. Its dysregulation contributes to the progression of fibrotic diseases in the liver, lungs, kidneys, and heart. Targeting NF-κB and its downstream pathways offers a promising therapeutic approach to mitigate fibrosis and prevent organ dysfunction in chronic diseases.